Abstract
Despite the use of standard adjuvant treatment (ACT) based on fluoropyrimidines plus oxaliplatin, up to 80% of patients with localized colorectal cancer (CC) presents detectable circulating tumor DNA (ctDNA) related with relapse. No biomarkers of response and resistance to ACT have been clarified and the molecular mechanisms of relapse remain unknown. Our aim is to identify the dynamic molecular changes at relapse, intratumoral heterogeneity (ITH) and potential novel therapeutic approaches to eradicate residual disease.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
